Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Verona Pharma

Home Clinical Trial Sponsors and OrganizationsVerona Pharma

Verona Pharma

ACTIVE

3 More London Riverside, London, United Kingdomwww.veronapharma.comPublic79 employeesEstablished: 2005-01-01

Also known as:

VRNA

维罗纳制药

vrna-us

verona pharma plc

Verona Pharma Plc engages in the development and commercialization of therapeutics for the treatment of respiratory diseases. It focuses on developing inhaled ensifentrine for the maintenance treatment of chronic obstructive pulmonary disease. The company was founded by Michael J. A. Walker and Clive P. Page on February 24, 2005 and is headquartered in London, the United Kingdom.

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Clinical Trials

47

25 active

Approvals

0

Total approvals

Agencies

0

Regulatory bodies

Founded

2005

Overview

Trial Phase Distribution

Phase

Trials

Share

Phase 1

22

46.8%

Phase 2

17

36.2%

Phase 3

3

6.4%

Trial Status Distribution

Active, not recruiting

25

53.2%

Completed

19

40.4%

Recruiting

3

6.4%

Clinical Trials

Trials sponsored by this organization (47)

A Phase II Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Single Inhaled Doses of Ensifentrine-glycopyrrolate Fixed Dose Combination, Ensifentrine, and Glycopyrrolate in Subjects With Chronic Obstructive Pulmonary Disease

Oct 202533 participants

Clinical Study of Ensifentrine-Glycopyrrolate (MK-5884A/RPL554) Fixed-dose Combination Dose Ranging in Participants With COPD (MK-5884A-029/RPL554-CO-212)

Jul 2025497 participants

A Phase II Study of Ensifentrine in Non-Cystic Fibrosis Bronchiectasis

Sep 2024284 participants

A Phase IIb Study of Glycopyrrolate Inhalation Solution Over 1 Week in Subjects With COPD

Aug 202446 participants

Effect of Ensifentrine Treatment on CAT Score

Jun 202420 participants

Effect of Ensifentrine on Sputum Markers of Inflammation in COPD

May 202256 participants

A Phase III randomized, placebo-controlled study to evaluate the efficacy and safety of ensifentrine over 24 weeks in patients with chronic obstructive pulmonary disease.

Active, not recruiting

Nov 2020800 participants

A Phase III randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of ensifentrine over 24 weeks (with a 48-week safety subset) in patients with moderate to severe chronic obstructive pulmonary disease.

Active, not recruiting

Oct 2020800 participants

Page 1 of 6

Approvals

No approval data available

News

No news articles found

On this page

Overview
Clinical Trials47
Approvals
News

Back to Organizations